𝔖 Bobbio Scriptorium
✦   LIBER   ✦

MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION

✍ Scribed by Thomas, H.C; Carman, W.F; Hadziyannis, S; Mcgarvey, M.J; Jacyna, M.R; Karayiannis, P; Makris, A

Book ID
123538880
Publisher
The Lancet
Year
1989
Tongue
English
Weight
684 KB
Volume
334
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dane Particle-Associated Hepatitis B e A
Dane Particle-Associated Hepatitis B e Antigen in Patients with Chronic Hepatitis B Virus Infection and Hepatitis B e Antibody
✍ Giovanni Raimondo; Serafino Recchia; Carla Lavarini; Osvaldo Crivelli; Mario Riz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 642 KB

A commercial radioimmunoassay was adapted to detect serum Dane particle-associated HBeAg in patients whose sera contained the homologous antibody. HBeAg was released from Dane particles with guanidine HC1. Dane particles were separated from anti-HBe by gel-filtration (Sepharose 4B) and ultracentrif

Characterization of viral kinetics in pa
Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B
✍ I-Chin Wu; Nan-Haw Chow; Pin-Nan Cheng; Wen-Chun Liu; Kung-Chia Young; Wei-Lun C 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract A study was conducted during a 1 year follow‐up to characterize the viral kinetics in hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B and to develop a model of predicting the probability of spontaneous HBeAg seroconversion. Fifty‐seven patients with HBeAg‐positive chronic hep

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60